We narrowed to 101 results for: RHO

1. pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (AAV5)

   Viral Prep

   #20297-AAV5

   Purpose

   Ready-to-use AAV5 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   mCherry (Cre-dependent)

   Available since

   Feb. 15, 2018

   Availability

   Academic Institutions and Nonprofits only

2. pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (AAV8)

   Viral Prep

   #20297-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   mCherry (Cre-dependent)

   Available since

   Dec. 18, 2017

   Availability

   Academic Institutions and Nonprofits only

3. pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (AAV1)

   Viral Prep

   #20297-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   mCherry (Cre-dependent)

   Available since

   Feb. 15, 2018

   Availability

   Academic Institutions and Nonprofits only

4. pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (AAV9)

   Viral Prep

   #20298-AAV9

   Purpose

   Ready-to-use AAV9 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   EYFP (Cre-dependent)

   Available since

   March 30, 2018

   Availability

   Academic Institutions and Nonprofits only

5. pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (AAV5)

   Viral Prep

   #20298-AAV5

   Purpose

   Ready-to-use AAV5 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   EYFP (Cre-dependent)

   Available since

   Feb. 15, 2018

   Availability

   Academic Institutions and Nonprofits only

6. pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (AAV1)

   Viral Prep

   #20298-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   EYFP (Cre-dependent)

   Available since

   Oct. 12, 2017

   Availability

   Academic Institutions and Nonprofits only

7. pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (AAV Retrograde)

   Viral Prep

   #20297-AAVrg

   Purpose

   Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   mCherry (Cre-dependent)

   Available since

   Aug. 22, 2017

   Availability

   Academic Institutions and Nonprofits only

8. pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (AAV PHP.eB)

   Viral Prep

   #20298-PHPeB

   Purpose

   Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   EYFP (Cre-dependent)

   Available since

   Sept. 8, 2020

   Availability

   Academic Institutions and Nonprofits only

9. AAV-FLEX-Arch-GFP (AAV9)

   Viral Prep

   #22222-AAV9

   Purpose

   Ready-to-use AAV9 particles produced from AAV-FLEX-Arch-GFP (#22222). In addition to the viral particles, you will also receive purified AAV-FLEX-Arch-GFP plasmid DNA. CAG-driven cre-dependent Arch-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Edward Boyden

   Article

   Chow et al Nature. 2010 Jan 7. 463(7277):98-102.

   Promoter

   CAG

   Tags

   GFP (Cre-dependent)

   Available since

   Feb. 20, 2018

   Availability

   Academic Institutions and Nonprofits only

10. pAAV-CamKII-ArchT-GFP (PV2527) (AAV1)

    Viral Prep

    #99039-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Edward Boyden

    Article

    Han et al Front Syst Neurosci. 2011;5:18. Epub 201

    Promoter

    CaMKII

    Tags

    GFP

    Available since

    Feb. 7, 2018

    Availability

    Academic Institutions and Nonprofits only

11. pAAV-Syn-ChR2(H134R)-GFP (AAV Retrograde)

    Viral Prep

    #58880-AAVrg

    Purpose

    Ready-to-use AAV Retrograde particles produced from pAAV-Syn-ChR2(H134R)-GFP (#58880). In addition to the viral particles, you will also receive purified pAAV-Syn-ChR2(H134R)-GFP plasmid DNA. Humanized channelrhodopsin H134R mutant fused to GFP, under the control of the Synapsin promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Edward Boyden

    Article

    Boyden et al Nat Neurosci. 2005 Sep . 8(9):1263-8.

    Promoter

    Syn

    Tags

    GFP

    Available since

    June 20, 2017

    Availability

    Academic Institutions and Nonprofits only

12. pAAV-CamKII-ArchT-GFP (PV2527) (AAV5)

    Viral Prep

    #99039-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition.

    Depositor

    Edward Boyden

    Article

    Han et al Front Syst Neurosci. 2011;5:18. Epub 201

    Promoter

    CaMKII

    Tags

    GFP

    Available since

    Feb. 21, 2018

    Availability

    Academic Institutions and Nonprofits only

13. AAV-FLEX-Arch-GFP (AAV1)

    Viral Prep

    #22222-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from AAV-FLEX-Arch-GFP (#22222). In addition to the viral particles, you will also receive purified AAV-FLEX-Arch-GFP plasmid DNA. CAG-driven cre-dependent Arch-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Edward Boyden

    Article

    Chow et al Nature. 2010 Jan 7. 463(7277):98-102.

    Promoter

    CAG

    Tags

    GFP (Cre-dependent)

    Available since

    Feb. 21, 2018

    Availability

    Academic Institutions and Nonprofits only

14. pAAV-FLEX-ArchT-tdTomato (AAV5)

    Viral Prep

    #28305-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from pAAV-FLEX-ArchT-tdTomato (#28305). In addition to the viral particles, you will also receive purified pAAV-FLEX-ArchT-tdTomato plasmid DNA. CAG-driven Cre-dependent ArchT-tdTomato expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Edward Boyden

    Article

    Han et al Front Syst Neurosci. 2011;5:18. Epub 201

    Promoter

    CAG

    Tags

    tdTomato (Cre-dependent)

    Available since

    Feb. 7, 2018

    Availability

    Academic Institutions and Nonprofits only

15. pAAV-CamKII-ArchT-GFP (PV2527) (AAV Retrograde)

    Viral Prep

    #99039-AAVrg

    Purpose

    Ready-to-use AAV Retrograde particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Edward Boyden

    Article

    Han et al Front Syst Neurosci. 2011;5:18. Epub 201

    Promoter

    CaMKII

    Tags

    GFP

    Available since

    May 15, 2019

    Availability

    Academic Institutions and Nonprofits only

16. pAAV-hsyn-Jaws-KGC-GFP-ER2 (AAV5)

    Viral Prep

    #65014-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from pAAV-hsyn-Jaws-KGC-GFP-ER2 (#65014). In addition to the viral particles, you will also receive purified pAAV-hsyn-Jaws-KGC-GFP-ER2 plasmid DNA. hSyn-driven Jaws-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Edward Boyden

    Article

    Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

    Promoter

    Syn

    Tags

    GFP

    Available since

    Feb. 7, 2018

    Availability

    Academic Institutions and Nonprofits only

17. pAAV-hsyn-Jaws-KGC-GFP-ER2 (AAV8)

    Viral Prep

    #65014-AAV8

    Purpose

    Ready-to-use AAV8 particles produced from pAAV-hsyn-Jaws-KGC-GFP-ER2 (#65014). In addition to the viral particles, you will also receive purified pAAV-hsyn-Jaws-KGC-GFP-ER2 plasmid DNA. hSyn-driven Jaws-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Edward Boyden

    Article

    Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

    Promoter

    Syn

    Tags

    GFP

    Available since

    Oct. 13, 2017

    Availability

    Academic Institutions and Nonprofits only

18. pAAV-CAG-DIO-ChR2(H134R)-eYFP (AAV PHP.eB)

    Viral Prep

    #127090-PHPeB

    Purpose

    Ready-to-use AAV PHP.eB particles produced from pAAV-CAG-DIO-ChR2(H134R)-eYFP (#127090). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-ChR2(H134R)-eYFP plasmid DNA. CAG-driven, Cre-dependent expression of humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Viviana Gradinaru

    Article

    Rajendran et al Nat Commun. 2019 Apr 26;10(1):1944. doi:

    Promoter

    CAG

    Tags

    EYFP (Cre-dependent)

    Available since

    July 28, 2020

    Availability

    Academic Institutions and Nonprofits only

19. pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (AAV8)

    Viral Prep

    #84446-AAV8

    Purpose

    Ready-to-use AAV8 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (#84446). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] plasmid DNA. CAG-driven, Cre-dependent expression of Jaws-KGC-tdTomato-ER2 for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Edward Boyden

    Article

    Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

    Promoter

    CAG

    Tags

    None

    Available since

    June 21, 2024

    Availability

    Academic Institutions and Nonprofits only

20. pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (AAV1)

    Viral Prep

    #84446-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (#84446). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] plasmid DNA. CAG-driven, Cre-dependent expression of Jaws-KGC-tdTomato-ER2 for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Edward Boyden

    Article

    Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

    Promoter

    CAG

    Tags

    tdTomato

    Available since

    March 18, 2024

    Availability

    Academic Institutions and Nonprofits only